Attending AACR 2026?
Don't go in blind. Get our curated networking cheatsheet with party lists & investor maps.
Join 5,000+ Life Science Leaders
Official Registration
Visit Official Website ↗Strategic Context
Attendees can present and learn about the latest advances in cancer research, network with leading experts, and explore new technologies and therapeutic strategies. The meeting offers extensive educational and training opportunities, fostering collaboration and career development in the oncology field.
Who Attends
Cancer Researchers, Health Care Professionals, Patient Advocates
Accommodation for AACR 2026 typically sells out 3–4 months in advance. We recommend booking hotels near the venue immediately after registration opens.
Coverage from AACR 2026
NK Cell Immunotherapy: Biology to Clinic at AACR 2026
Natural killer (NK) cell-based immunotherapies are emerging as a promising cancer treatment strategy, with ongoing clinical trials exploring their efficacy.
Cancer Therapies Induce Lifespan Comorbidities: ACCR 2026 Review
Cancer therapies, while life-saving, induce significant long-term comorbidities across all age groups, necessitating integrated survivorship care.
HTAN Decodes Tumor Evolution: Ecological Perspective at AACR2026
Understanding tumor evolution is critical for effective cancer therapy. The Human Tumor Atlas Network (HTAN) provides an ecological and evolutionary framework.
MAVEs Inform Variant Interpretation in Clinical Oncology Practice
Multiplex Assays of Variant Effects (MAVEs) offer a systematic approach to interpreting genetic variants in oncology, addressing current limitations in variant classification.
AI in Oncology: Practical Applications Transforming Cancer Care
AI integration in oncology is moving beyond theoretical promise to deliver tangible benefits in diagnosis, treatment planning, and patient management.
DNA Methylation Patterns Emerge as Sarcoma Biomarkers
Sarcomas present diagnostic and therapeutic challenges due to their heterogeneous nature. DNA methylation profiling may enhance early diagnosis and personalized treatment.
Next-Gen Extracellular Vesicles: Biomarkers, Targets, Deliverables in Oncology
Extracellular vesicles (EVs) and particles (EPs) offer new avenues for cancer diagnosis, prognosis, and therapy. Their role as biomarkers and drug delivery systems is expanding.